What are the side effects of sirolimus albumin-bound nanoparticle injection (FYARRO)?

In clinical studies of sirolimus albumin-bound nanoparticle injection (FYARRO) in the treatment of perivascular epithelioid cell tumors (PEComa) , the most common (≥30%) adverse reactions were stomatitis, fatigue, rash, infection, nausea, edema, diarrhea, musculoskeletal pain, weight loss, decreased appetite, cough, vomiting, and taste disturbance. The most common (≥6%) grade 3-4 laboratory abnormalities were lymphopenia, increased glucose, decreased potassium, decreased phosphate, decreased hemoglobin, and increased lipase.

Serious adverse reactions in patients treated with sirolimus albumin-bound nanoparticle injection included infection, abdominal pain, dehydration and upper gastrointestinal bleeding.One patient who received treatment experienced fatal adverse reactions and developed upper gastrointestinal bleeding. Thirty-five percent of patients had dose reductions due to adverse reactions, including stomatitis and pneumonitis; 65% of patients had dose interruptions due to adverse reactions, including stomatitis, pneumonitis, anemia, dehydration, acneiform dermatitis, and thrombocytopenia. Nine percent of patients permanently discontinued treatment due to adverse reactions, including pneumonia, anemia, and non-infectious cystitis.

The original drug of sirolimus albumin-bound nanoparticle injection has not yet been marketed in China, so it is not included in medical insurance. The US version of sirolimus albumin-bound nanoparticle injection Original drug, specifications The price of each 100mg tube may be around RMB 60,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Sirolimus Albumin-Bound Nanoparticle Injection on the market. For more drug information and specific prices, please consult Yaode Medical Consultants.